Here are four things to know:
1. The lumbar intervertebral body fusion device is indicated for use with autogenous bone graft in patients with degenerative disc disease at one or two contiguous levels from L2-S1.
2. Surgeons can implant the device via posterior, transforaminal or lateral approach. It also aims to provide for optimum graft injection through its patented delivery system.
3. The device joins the Interventional Spine family of Opticage Expandable Interbody Fusion Devices, which received FDA clearance late last year.
4. Interventional Spine is currently in the process of assessing other sizes and configurations for its line of Lordotic Expandable Opticages.
More articles on devices:
J&J ramps up medical device business, plans to launch 20+ products by 2018: 7 key notes
Dr. David Manning to perform TKR using Medacta’s integrated knee platform — 5 notes
FDA approves Boston Scientific’s new SCS system: 3 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
